EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

ASIA VETS HOLDINGS LTD. (5RE) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of ASIA VETS HOLDINGS LTD. S$0.06, price S$0.08, upside -20.0%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · SG · ISIN SG2B95959500

AV Thin data Oct 2, 2026

ASIA VETS HOLDINGS LTD.

5RE · SG

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value 0.0640 SGD · Overvalued (−20.0%)
!Quality 53/100
!Weak Growth (revenue 5y −11.7 %/yr)
✓Low debt · generates free cash flow
!Trails peers (2/10)
!Narrow moat 0/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 7 out of 100
!Weak on future: 3 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

0.1050 SGD 0.0210 SGD Fair Value 0.0640 SGD Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range 0.0210 SGD – 0.1050 SGD · the 0.0800 SGD price screens above the 0.0640 SGD fair value. Dashed = 300-day average. As of Oct 2, 2026.

Follow ASIA VETS HOLDINGS in your weekly email

Every Wednesday you see whether ASIA VETS HOLDINGS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Asia Vets Holdings Ltd., through its subsidiary, AVH Animal Ark Pte. Ltd., provides veterinary care and clinical services to small animals in Singapore.

Show more

Asia Vets Holdings Ltd., through its subsidiary, AVH Animal Ark Pte. Ltd., provides veterinary care and clinical services to small animals in Singapore. The company operates two veterinary clinics, which provides general veterinary services including medical, surgical, and dental care for small animals, such as dogs, cats, rabbits, hamsters, guinea pigs, and chinchillas. It also provides vaccination, health check, dentistry, acupuncture, and traditional Chinese medicines; and natural killer cell and stem cell therapies, in-house blood tests, such as biochemistry and hematology, interventional radiology and endoscopy, surgery and invasive procedures, and pet diet prescription services, as well as diagnostic imaging, which includes ultrasonography, digital radiography, laparoscopy, and endoscopy. Asia Vets Holdings Ltd. was formerly known as Smartflex Holdings Ltd. and changed its name to Asia Vets Holdings Ltd. in July 2018. The company was incorporated in 2010 and is headquartered in Singapore. Asia Vets Holdings Ltd. operates as a subsidiary of Tan Gee Beng Pte. Ltd.

Stock analysis

ASIA VETS HOLDINGS LTD. (5RE) currently trades at 0.0800 SGD, while our model-based Fair Value estimate is 0.0640 SGD, 20.0% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 0.0600 SGD per share, and 0 of the 7 models we run sit above the 0.0800 SGD price.

Bear case: the Asset-Based group reads lowest at 0.0400 SGD, and 7 of the 7 models stay below the price. Evidence for this calculation is low.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

ASIA VETS HOLDINGS LTD. reported revenue of 2.3M SGD in FY2025 versus 3.1M SGD in FY2021, a compound −6.7%/yr. Reported net income was −6.5M SGD in FY2025.

Key figures

Market cap 11.7M SGD (≈ $9.1M) · P/S ratio 4.72 · EPS (TTM) −0.0400 SGD · Net margin −279% · Return on equity −51.2% · Return on assets (EBIT) −5.2% · Operating margin −39.6% · Revenue (TTM) 2.3M SGD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 24% below its 52-week high and 220% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −20%, 5RE screens richer than that median.

Fair Value models

Bear 0.0640 SGD Fair Value 0.0640 SGD Bull 0.0640 SGD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 0.0600 SGD 0.0600 SGD 0.0600 SGD 82
Growth DCF 0.0600 SGD 0.0600 SGD 0.0600 SGD 80
5Y Revenue Exit 0.0600 SGD 0.0600 SGD 0.0600 SGD 74
All 7 models by family
DCF Models
FCF DCF 0.0600 SGD 0.0600 SGD 0.0600 SGD 82
5Y Revenue Exit 0.0600 SGD 0.0600 SGD 0.0600 SGD 74
10Y Revenue Exit 0.0600 SGD 0.0600 SGD 0.0600 SGD 68
Multiples
EV/Revenue 0.0600 SGD 0.0600 SGD 0.0600 SGD 54
Asset-Based
NCAV (Graham) 0.0300 SGD 0.0400 SGD 0.0600 SGD 54
Growth DCF
Growth DCF 0.0600 SGD 0.0600 SGD 0.0600 SGD 80
Rev-Margin DCF 0.0600 SGD 0.0600 SGD 0.0600 SGD 74

Open the full fair value analysis →

Notify me when 5RE reaches fair value

Put 5RE on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 53/100

Of which business quality 56 · Market factors (momentum, volatility) 56

Profitability 4
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 46
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 33
Calm price path (market factor)
Momentum 54
Price trend over the last 3–12 months (market factor)
52W Momentum 84
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 7/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−8.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.7%
Start year 2020 (pandemic)
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.2% (2020) → −40.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

5RE screens overvalued: fair value 20% below the price. Compare with HCA Healthcare, Inc →

Compare ASIA VETS HOLDINGS LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 244 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Below median
Fair Value upside −20.0% · Below median
Profitability
Return on assets −4.4% · Bottom 25%
Operating margin (TTM) −39.6% · Bottom 25%
Growth and dividend
Revenue growth 0.6% · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 0.97× · Cheapest 25%
P/S (TTM) 3.93× · Priciest 25%
P/FCF 126.5× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 33
FUTURE (revenue growth)3 · sector 30
PAST (return on equity)0 · sector 31
HEALTH (low debt)100 · sector 89
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $431.63 $597.97 +39%
Fresenius SE FRE €46.15 €34.49 −25%
Dr. Sulaiman Al Habib Medical Services Group 4013 225.00 SAR 109.45 SAR −51%
Tenet Healthcare Corporation THC $257.93 $274.35 +6%
IHH Healthcare Berhad, an investment holding company, 5225 8.03 MYR 4.87 MYR −39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,889 ₹2,908 −67%
Encompass Health Corporation EHC $123.47 $94.47 −23%
Fresenius Medical Care AG FMS $22.27 $45.84 +106%
DaVita Inc DVA $178.07 $215.81 +21%
Aier Eye Hospital Group 300015 ¥7.91 ¥10.86 +37%

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "ASIA VETS HOLDINGS LTD. Fair Value". https://www.fairvalue-calculator.com/stock/5RE

Frequently asked questions

Is ASIA VETS HOLDINGS LTD. (5RE) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 0.0640 SGD versus a price of 0.0800 SGD, about −20% upside (overvalued).
What is the fair value of 5RE?
Our model-based fair value for ASIA VETS HOLDINGS LTD. is 0.0640 SGD (as of Oct 2, 2026), built from audited fundamentals. The current price: 0.0800 SGD.
What is the quality score of 5RE?
ASIA VETS HOLDINGS LTD. has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ASIA VETS HOLDINGS LTD. (5RE)?
Our model-based price target is the fair value of 0.0640 SGD (as of Oct 2, 2026) from 7 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the ASIA VETS HOLDINGS LTD. stock forecast for 2026?
Our models put fair value at 0.0640 SGD, about −20% upside versus a price of 0.0800 SGD (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of ASIA VETS HOLDINGS LTD. (5RE)?
ASIA VETS HOLDINGS LTD. reported trailing-twelve-month revenue of about 2.3M SGD (latest available figure, as of Oct 2, 2026).
What growth is priced into ASIA VETS HOLDINGS LTD. (5RE)?
For today's price to be fair in a discounted-cash-flow model, ASIA VETS HOLDINGS LTD. would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -11.7 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of 5RE use?
Our models discount ASIA VETS HOLDINGS LTD. at 9.3 %: a base by market capitalisation (nano), damped by beta 0.93, country premium for Singapore. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ASIA VETS HOLDINGS LTD. that is less than minus 40 % per year a year over ten years, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has ASIA VETS HOLDINGS LTD. (5RE) delivered so far?
Over the past 5 years revenue at ASIA VETS HOLDINGS LTD. grew -11.7 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ASIA VETS HOLDINGS LTD. (5RE) growing?
The median revenue growth in the sector is +4.6 % a year. That is the yardstick for the growth priced into ASIA VETS HOLDINGS LTD. (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ASIA VETS HOLDINGS LTD. (5RE)?
The free-cash-flow yield on the price is 0.62 %: that much free cash flow ASIA VETS HOLDINGS LTD. produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ASIA VETS HOLDINGS LTD. (5RE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ASIA VETS HOLDINGS LTD. it is 0.0640 SGD per share (as of Oct 2, 2026), against a price of 0.0800 SGD. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is ASIA VETS HOLDINGS LTD. stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 5RE trades above its calculated fair value: price 0.0800 SGD, fair value 0.0640 SGD, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 5RE?
No. The price is what the market pays today (0.0800 SGD); the fair value is what the company's own numbers justify (0.0640 SGD). For ASIA VETS HOLDINGS LTD. the two are 0.0160 SGD per share apart. That gap is exactly why we show both numbers side by side.
How much is ASIA VETS HOLDINGS LTD. worth?
The market values ASIA VETS HOLDINGS LTD. at about 11.7M SGD (market capitalisation, as of Oct 2, 2026). Per share that is 0.0800 SGD; our models calculate a fair value of 0.0640 SGD per share.
How solid is the balance sheet of ASIA VETS HOLDINGS LTD. (5RE)?
Balance-sheet figures for ASIA VETS HOLDINGS LTD. (as of Oct 2, 2026): return on equity −51.2%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 5RE from its 52-week high?
ASIA VETS HOLDINGS LTD. trades at 0.0800 SGD, about 24% below its 52-week high of 0.1050 SGD and 220% above the low of 0.0250 SGD (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of 0.0640 SGD is for.
Which stocks are comparable to ASIA VETS HOLDINGS LTD.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ASIA VETS HOLDINGS LTD. stock attractive at the current price?
The data as of Oct 2, 2026: price 0.0800 SGD, calculated fair value 0.0640 SGD (−20%), Quality Score 53/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 5RE calculated?
We run ASIA VETS HOLDINGS LTD. through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.0640 SGD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. ASIA VETS HOLDINGS LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ASIA VETS HOLDINGS LTD. (5RE)?
The closing price on Sep 30, 2026 was 0.0800 SGD. Our model-based fair value is 0.0640 SGD, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ASIA VETS HOLDINGS LTD. right now?
The price sits above even our optimistic bull case (0.0640 SGD). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of ASIA VETS HOLDINGS LTD.

How large is the market capitalisation of ASIA VETS HOLDINGS LTD. (5RE)?
The market capitalisation of ASIA VETS HOLDINGS LTD. is 11.7M SGD (≈ $9.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ASIA VETS HOLDINGS LTD. (5RE)?
The price-to-sales ratio of ASIA VETS HOLDINGS LTD. is 4.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ASIA VETS HOLDINGS LTD. (5RE)?
Earnings per share at ASIA VETS HOLDINGS LTD. are −0.0400 SGD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of ASIA VETS HOLDINGS LTD. (5RE)?
The net margin of ASIA VETS HOLDINGS LTD. is −279% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ASIA VETS HOLDINGS LTD. (5RE)?
The return on equity (ROE) of ASIA VETS HOLDINGS LTD. is −51.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ASIA VETS HOLDINGS LTD. (5RE)?
On an EBIT basis the return on assets of ASIA VETS HOLDINGS LTD. is −5.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ASIA VETS HOLDINGS LTD. (5RE)?
The operating margin of ASIA VETS HOLDINGS LTD. is −39.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ASIA VETS HOLDINGS LTD. (5RE)?
Revenue at ASIA VETS HOLDINGS LTD. is growing +0.6% versus a year earlier (3y avg −1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ASIA VETS HOLDINGS LTD. (5RE)?
Earnings per share at ASIA VETS HOLDINGS LTD. are growing −52.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch ASIA VETS HOLDINGS LTD. in the live analysis

One click puts ASIA VETS HOLDINGS LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.